Literature DB >> 23481684

Oligomeric pyroglutamate amyloid-β is present in microglia and a subfraction of vessels in patients with Alzheimer's disease: implications for immunotherapy.

Oliver Wirths1, Antje Hillmann, Laurent Pradier, Wolfgang Härtig, Thomas A Bayer.   

Abstract

N-terminally truncated pyroglutamate amyloid-β (Aβ) starting at position 3 (AβpE3) represents a major fraction of Aβ peptides in Alzheimer's disease (AD). Recently, we have identified low molecular weight AβpE3 oligomers, which can be detected by 9D5, a novel mouse monoclonal antibody. In the present study, we analyzed the immunohistochemical staining profile in the brain of patients with AD and in the APP/PS1KI mouse model, as well as in aged rhesus monkeys. 9D5-positive microglia and blood vessels were found in many AD cases, in the transgenic mouse model, and in an aged macaque. The presence of 9D5-immunoreactivity in microglia indicates that low molecular weight AβpE3 oligomers may be phagocytosed, since in the APP/PS1KI model, Aβ is exclusively produced in neurons due to neuronal expression of transgenic AβPP.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23481684     DOI: 10.3233/JAD-121945

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  7 in total

1.  Aβ truncated species: Implications for brain clearance mechanisms and amyloid plaque deposition.

Authors:  Erwin Cabrera; Paul Mathews; Emiliya Mezhericher; Thomas G Beach; Jingjing Deng; Thomas A Neubert; Agueda Rostagno; Jorge Ghiso
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-07-13       Impact factor: 5.187

2.  Mitochondrial dysfunction induced by a post-translationally modified amyloid linked to a familial mutation in an alternative model of neurodegeneration.

Authors:  Krysti Todd; Silvia Fossati; Jorge Ghiso; Agueda Rostagno
Journal:  Biochim Biophys Acta       Date:  2014-09-28

3.  The structure of the human glutaminyl cyclase-SEN177 complex indicates routes for developing new potent inhibitors as possible agents for the treatment of neurological disorders.

Authors:  Cecilia Pozzi; Flavio Di Pisa; Manuela Benvenuti; Stefano Mangani
Journal:  J Biol Inorg Chem       Date:  2018-08-21       Impact factor: 3.358

4.  N-terminally truncated Aβ4-x proteoforms and their relevance for Alzheimer's pathophysiology.

Authors:  Agueda Rostagno; Erwin Cabrera; Tammaryn Lashley; Jorge Ghiso
Journal:  Transl Neurodegener       Date:  2022-06-01       Impact factor: 9.883

5.  Markers of microglia in post-mortem brain samples from patients with Alzheimer's disease: a systematic review.

Authors:  K E Hopperton; D Mohammad; M O Trépanier; V Giuliano; R P Bazinet
Journal:  Mol Psychiatry       Date:  2017-12-12       Impact factor: 15.992

6.  Repurposing FDA-Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease.

Authors:  Chenshu Xu; Haoman Zou; Xi Yu; Yazhou Xie; Jiaxin Cai; Qi Shang; Na Ouyang; Yinan Wang; Pan Xu; Zhendan He; Haiqiang Wu
Journal:  ChemistryOpen       Date:  2020-12-30       Impact factor: 2.630

Review 7.  Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease.

Authors:  Thomas A Bayer; Oliver Wirths
Journal:  Acta Neuropathol       Date:  2014-05-07       Impact factor: 17.088

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.